Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$1.18 -1.7%	$1.77	$1.09 ▼ $7.67	$14.76M	0.66	52,082 shs	126,942 shs
HOTH Hoth Therapeutics	$1.17 +3.5%	$1.03	$0.58 ▼ $3.80	$14.93M	0.55	3.71 million shs	412,756 shs
MRKR Marker Therapeutics	$1.53 +4.8%	$1.34	$0.95 ▼ $5.99	$16.52M	1.44	79,758 shs	52,512 shs
THAR Tharimmune	$1.94 +7.6%	$1.47	$0.95 ▼ $6.39	$4.80M	1.04	371,732 shs	68,397 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	0.00%	-9.43%	-37.17%	-44.44%	-78.18%
HOTH Hoth Therapeutics	0.00%	-6.61%	+34.62%	+13.00%	+24.27%
MRKR Marker Therapeutics	0.00%	+0.69%	-5.82%	+18.70%	-73.11%
THAR Tharimmune	0.00%	+34.51%	+20.97%	+32.54%	-48.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CASI CASI Pharmaceuticals	4.5553 of 5 stars	3.5	5.0	4.3	3.8	1.7	0.0
HOTH Hoth Therapeutics	2.0382 of 5 stars	3.6	2.0	0.0	2.4	0.0	0.6
MRKR Marker Therapeutics	4.2285 of 5 stars	3.8	3.0	3.9	2.7	0.8	0.6
THAR Tharimmune	3.5312 of 5 stars	3.8	5.0	0.0	3.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	238.98% Upside
HOTH Hoth Therapeutics	3.25	Buy	$4.00	241.88% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	760.57% Upside
THAR Tharimmune	3.50	Strong Buy	$17.00	776.20% Upside

Current Analyst Ratings Breakdown

Latest THAR, MRKR, HOTH, and CASI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/15/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/9/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
4/1/2025	MRKR Marker Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$12.50 ➝ $12.50
3/31/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$28.54M	0.51	N/A	N/A	$0.12 per share	9.83
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
MRKR Marker Therapeutics	$6.59M	2.63	N/A	N/A	$1.73 per share	0.88
THAR Tharimmune	N/A	N/A	N/A	N/A	$0.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/15/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
MRKR Marker Therapeutics	-$10.73M	-$1.33	N/A	N/A	N/A	-224.46%	-101.87%	-83.02%	8/13/2025 (Estimated)
THAR Tharimmune	-$12.20M	-$7.88	N/A	∞	N/A	N/A	-489.33%	-264.34%	N/A

Latest THAR, MRKR, HOTH, and CASI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A
5/12/2025	Q1 2025	THAR Tharimmune	-$0.84	-$0.99	-$0.15	-$0.99	N/A	N/A
3/31/2025	Q4 2024	CASI CASI Pharmaceuticals	-$0.60	-$0.79	-$0.19	-$0.79	$7.39 million	$13.36 million
3/31/2025	Q4 2024	MRKR Marker Therapeutics	-$0.28	-$0.42	-$0.14	-$0.42	$5.25 million	$1.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
THAR Tharimmune	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	N/A	0.81	0.68
HOTH Hoth Therapeutics	N/A	15.09	15.08
MRKR Marker Therapeutics	N/A	6.79	6.79
THAR Tharimmune	N/A	0.67	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
HOTH Hoth Therapeutics	7.08%
MRKR Marker Therapeutics	22.39%
THAR Tharimmune	1.16%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
HOTH Hoth Therapeutics	6.92%
MRKR Marker Therapeutics	14.50%
THAR Tharimmune	10.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
MRKR Marker Therapeutics	60	11.31 million	9.67 million	Not Optionable
THAR Tharimmune	2	2.66 million	2.40 million	Not Optionable

THAR, MRKR, HOTH, and CASI Headlines

Recent News About These Companies

Monday’s Insider Moves: Top Buys and Sells in US Stocks

June 24, 2025 | investing.com

Tharimmune, Inc. (NASDAQ:THAR) CEO Sireesh Appajosyula Acquires 61,496 Shares

June 24, 2025 | insidertrades.com

Tharimmune CFO Don Kim Resigns

June 17, 2025 | marketwatch.com

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

June 17, 2025 | accessnewswire.comA

Tharimmune announces executive changes and new agreements

June 13, 2025 | investing.com

Tharimmune advances opioid prophylaxis drug TH104

May 7, 2025 | investing.com

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025 | accessnewswire.comA

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025 | accessnewswire.comA

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

April 30, 2025 | accessnewswire.comA

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

April 28, 2025 | sacbee.comS

Tharimmune announces board retirements ahead of annual meeting

April 26, 2025 | investing.com

Tharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

April 15, 2025 | finanznachrichten.de

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

April 15, 2025 | accessnewswire.comA

Tharimmune reports data on new biparatopic biologics

April 9, 2025 | bioworld.comB

Tharimmune announces preclinical data from expanded pipeline with HS1940

April 9, 2025 | markets.businessinsider.com

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

April 7, 2025 | accessnewswire.comA

Tharimmune receives Nasdaq non-compliance notice

April 6, 2025 | investing.com

Tharimmune announces FDA feedback on NDA path for TH104

April 1, 2025 | markets.businessinsider.com

Tharimmune announces FDA feedback on TH104 NDA path

April 1, 2025 | markets.businessinsider.com

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

March 31, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR, MRKR, HOTH, and CASI Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$1.18 -0.02 (-1.67%)

As of 03:46 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Hoth Therapeutics NASDAQ:HOTH

$1.17 +0.04 (+3.54%)

As of 04:00 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Marker Therapeutics NASDAQ:MRKR

$1.53 +0.07 (+4.79%)

As of 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Tharimmune NASDAQ:THAR

$1.94 +0.14 (+7.64%)

As of 03:59 PM Eastern

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time